ArticleFrontiers in oncology2021
Refractory Head and Neck Lymphatic Malformation in Infants Treated With Sirolimus: A Case Series.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Sirolimus for vascular anomalies in the first year of life: a systematic review.Journal of perinatology : official journal of the California Perinatal Association · 2024Pooled it
- Sirolimus treatment for paediatric head and neck lymphatic malformations: a systematic review.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023Pooled it
- Efficacy of sirolimus in children with lymphatic malformations of the head and neck.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022Pooled it
- Case Report: CLAPO syndrome: a case management and literature review.Frontiers in pediatrics · 2026Article
- Case Report: Lymphatic malformation in a paediatric patient with a 7-year follow-Up.Frontiers in pediatrics · 2026Article
- A real-world study of sirolimus in the treatment of pediatric head and neck lymphatic malformations.Journal of vascular surgery. Venous and lymphatic disorders · 2025Article
- Ultrasound-guided sclerotherapy of pingyangmycin for periorbital lymphatic malformations.BMC ophthalmology · 2025Article
- Lymphatic malformations involving the thorax in children: a retrospective cohort study.BMC pulmonary medicine · 2025Article
- New Insights into Cervicofacial Vascular Anomalies.Journal of clinical medicine · 2024Review
- Pediatric Vascular Anomalies: A Clinical and Radiological Perspective.The Indian journal of radiology & imaging · 2024Review
- Alpelisib for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth.Genetics in medicine : official journal of the American College of Medical Genetics · 2022Article
- Multispecialty Approach to a Very Large Congenital Head and Neck Cystic Lymphatic Malformation in an Infant Born by SARS-CoV-2 Positive Mother-A Case Report.Biomedicines · 2022Article
- Laparoscopy for evaluating mesenteric lymphangiomatosis: A case report.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExtensive and complex head and neck lymphatic malformations (LMs) are challenging to manage through traditional therapy. The purpose of this retrospective study was to assess the efficacy and safety of sirolimus in infants with refractory head and neck LMs.
methodsSirolimus was administered orally on a continuous dosing schedule. Patients were seen every month for the first three months and then subsequently every three months. The primary endpoints were safety and efficacy based on clinical and radiological evaluations.
resultsEight patients, refractory to standard care, were enrolled and received sirolimus continuously. After 12 months of follow-up, the response and safety to medication was evaluated: all patients experienced reductions in LMs bulk, ranging from modest to significant. Some minor adverse effects were reported: mouth sores, eczema, gastrointestinal reaction, dyslipidemia, and neutropenia.
conclusionSirolimus was efficient in children with refractory head and neck LMs and was well tolerated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.